Inventor · disambiguated record
Beni B. Wolf
Also filed as: WOLF BENI · WOLF BENI B
11 granted patents·19 pending applications·95 citations·filing 2004–2025
90Inventor score
Files withIMMUNOGEN INC10GENENTECH INC9MERRIMACK PHARMACEUTICALS INC5BLUEPRINT MEDICINES CORP4IMMNOGEN INC1
Top patents by PatentIndex Score
30 records- 0194US9200073B2Diagnostic assays and kits for detection of folate receptor 1IMMUNOGEN INC·Filed 2013·Granted Dec 1, 2015·23 cites·15 claims
- 0293US10613093B2Diagnostic assays and kits for detection of folate receptor 1IMMUNOGEN INC·Filed 2018·Granted Apr 7, 2020·4 cites·17 claims
- 0392US11273160B2RET inhibitor for use in treating cancer having a RET alterationBLUEPRINT MEDICINES CORP·Filed 2020·Granted Mar 15, 2022·5 cites·14 claims
- 0492US9702881B2Diagnostic assays and kits for detection of folate receptor 1IMMUNOGEN INC·Filed 2015·Granted Jul 11, 2017·15 cites·27 claims
- 0590US10180432B2Diagnostic assays and kits for detection of folate receptor 1IMMUNOGEN INC·Filed 2017·Granted Jan 15, 2019·6 cites·17 claims
- 0690US7399869B2Fibroblast activation protein inhibitor compounds and methodsGENENTECH INC·Filed 2006·Granted Jul 15, 2008·23 cites·21 claims
- 0789US11872192B2RET inhibitor for use in treating cancer having a RET alterationBLUEPRINT MEDICINES CORP·Filed 2021·Granted Jan 16, 2024·2 cites·19 claims
- 0888US11963958B2RET inhibitor for use in treating cancer having a RET alterationRIGEL PHARMACEUTICALS INC·Filed 2020·Granted Apr 23, 2024·2 cites·24 claims
- 0979US2023213524A1Diagnostic assays and kits for detection of folate receptor 1IMMUNOGEN INC·Filed 2022·Application pending·0 cites
- 1078US7799899B2Compositions and methods relating to STOP-1GENENTECH INC·Filed 2004·Granted Sep 21, 2010·14 cites·19 claims
- 1177US2022378694A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2022·Application pending·0 cites
- 1277US2025262217A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2025·Application pending·0 cites
- 1372US9657108B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted May 23, 2017·1 cites·6 claims
- 1468US2021100795A1Ret inhibitor for use in treating cancer having a ret alterationBLUEPRINT MEDICINES CORP·Filed 2019·Application pending·0 cites
- 1565US2020333347A1Diagnostic Assays and Kits for Detection of Folate Receptor 1IMMNOGEN INC·Filed 2020·Application pending·0 cites
- 1665US2017239367A1Anti-folr1 immunoconjugate dosing regimensIMMUNOGEN INC·Filed 2016·Application pending·0 cites
- 1764US2006140961A1Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2006·Application pending·0 cites
- 1864US2020046634A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2019·Application pending·0 cites
- 1964US2017253662A1Dosage and administration of anti-egfr therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2063US9920131B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Mar 20, 2018·0 cites·18 claims
- 2161US2014363451A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2014·Application pending·0 cites
- 2257US2006147374A1Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2006·Application pending·0 cites
- 2357US2016251445A1Dosage and administration of anti-egfr therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2455US2004258696A1Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2004·Application pending·0 cites
- 2555US2008280856A1Fibroblast Activation Protein Inhibitor Compounds and MethodsGENENTECH INC·Filed 2008·Application pending·0 cites
- 2653US2007212735A1Compositions and Methods for the Diagnosis and Treatment of TumorGENENTECH INC·Filed 2006·Application pending·0 cites
- 2752US2005170368A1Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2004·Application pending·0 cites
- 2849US2021308134A1Treatment of egfr-mutant cancerBLUEPRINT MEDICINES CORP·Filed 2019·Application pending·0 cites
- 2939US2011112279A1Compositions and Methods Relating to STOP-1GENENTECH INC·Filed 2010·Application pending·0 cites
- 3030US2016311908A1Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Beni B. Wolf files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →